CD163 and metabolic syndrome: Therefore, the aim of this study was 1) to analyze the changes in plasma lipid profile of patients at risk for diabesity and with a full blown MetS with specific emphasis on SPC during the evolution of these pathological states, and 2) to correlate plasma lipid levels with body mass index and the low-grade inflammation marker sCD163.